The global kidney cancer therapeutics and diagnostics market is projected to register a CAGR of 5.52% between 2019 and 2028, and is anticipated to generate revenue of $ 7966.9 million by 2028. Kidney cancer is often associated with various comorbidities. Therefore, its timely diagnosis and therapy are of utmost importance for a better quality of life. Due to the rising prevalence of kidney cancer in every part of the world, various governments and research organizations have established several initiatives for cancer awareness that are illustrating broad approaches for preventing and monitoring cancer.
GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028
Global Kidney Cancer Therapeutics and Diagnostics Market by Cancer Type (Clear Cell Rcc, Papillary Rcc, Chromophobe Rcc, Urothelial Carcinoma/transitional Cell Carcinoma, Other Kidney Cancers) by Component (Drugs (Drugs by Therapeutic Class (Targeted Therapy, Immunotherapy, Other Therapeutic Class), Drugs by Pharmacologic Class(Angiogenesis Inhibitors, Mtor Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (Il-2))), Diagnostics) and by Geography.
The global kidney cancer therapeutics and diagnostics market is projected to register a CAGR of 5.52% between 2019 and 2028, and is anticipated to generate revenue of $ 7966.9 million by 2028.
Kidney cancer is often associated with various comorbidities. Therefore, its timely diagnosis and therapy are of utmost importance for a better quality of life. Due to the rising prevalence of kidney cancer in every part of the world, various governments and research organizations have established several initiatives for cancer awareness that are illustrating broad approaches for preventing and monitoring cancer.
To know more about this report, request a free sample copy
Key factors propelling the global kidney cancer therapeutics and diagnostics market growth are:
- Growing prevalence of kidney cancer cases
- According to the World Cancer Research Fund, 2018, kidney cancer was the ninth-most commonly acquired disease in men and the fourteenth most commonly acquired disease in women.
- As per the data of the American Cancer Society, 2020, renal cell carcinoma is quite common in men compared to women.
- Increasing usage of minimally invasive processes
- Surging research and development expenditure
Major growth restraining factors:
- High costs associated with the treatment and diagnosis of kidney cancer
- Low rate of success in the clinical trials of kidney cancer drugs
- One of the major reasons behind the low success rate of cancer drugs is the adverse effects posed by the targeted therapies and immunotherapies.
- Most of the targeted therapies in kidney cancer treatment are tablets, and these often lead to complications or risk of acquiring various conditions, such as diarrhea and liver problems, like hepatitis and elevated liver enzymes.
- Stringent regulations
The report scope of the global kidney cancer therapeutics and diagnostics market includes the segmentation analysis of cancer type and component. These segments are further classified to provide a detailed analysis of the studied market.
Market by Cancer Type:
- Clear cell RCC
- Clear cell RCC is both the dominating and leading cancer type. Patients with Clear cell RCC may have pain or feel tired. Occasionally, patients do not have any visible indications. Indications can comprise, pain, blood in the urine, weight loss, fever, feeling tired, and a lump.
- The treatment for patients with ccRCC entails immunotherapy, surgery, and targeted therapy. Targeted therapy marks the deviations in cancer cells that help them grow, divide, and spread.
- Papillary RCC
- Chromophobe RCC
- Urothelial Carcinoma/Transitional Cell Carcinoma
- Other Kidney Cancers
Geographically, the global kidney cancer therapeutics and diagnostics market has been segmented based on four major regions, which includes:
- North America: The United States and Canada
- North America dominated the global market in 2019. The market is expected to grow rapidly in the next few years, with much of the growth coming from the U.S. and emerging markets.
- According to the estimates of the American Cancer Society, it is estimated that, in 2020, there would be around 73,750 new cases of kidney cancer in the United States, and approximately 14,830 deaths from this disease.
- Europe: The United Kingdom, Germany, Italy, France, Belgium, Russia, Poland, and Rest of Europe
- Asia Pacific: India, Australia & New Zealand, China, South Korea, Japan, Thailand, Indonesia, Vietnam, and Rest of Asia Pacific
- Rest of World: Latin America, the Middle East & Africa
The major market players in the global kidney cancer therapeutics and diagnostics market are:
- Abbott laboratories
- Becton, Dickinson and Company (BD)
- Hoffmann-la Roche
- Novartis International AG
- Pfizer Inc
- Others
Key strategies adopted by some of the kidney cancer therapeutics and diagnostics companies:
In July 2020, Exelixis declared the Commencement of CONTACT-03 Phase 3 pivotal trial of cabozantinib in combination with atezolizumab in formerly treated metastatic renal carcinoma. Also, in August 2020, Merck Animal Health declared the accomplishment of its acquisition of IdentiGEN, a DNA-based animal traceability solution for Aquaculture and Livestock.
Key findings of the global kidney cancer therapeutics and diagnostics market:
- The development of highly specific drugs is propelling market growth prospects.
- Clear cell RCC is the highest revenue-generating kidney cancer type.
- The enhanced accuracy and speed of diagnosis are set to impact market growth.
Frequently Asked Questions & Answers (FAQ):
- Which is the fastest-growing country in the kidney cancer therapeutics and diagnostics market?
A: China is the fastest-growing country in the kidney cancer therapeutics and diagnostics market.
- What is the scope of entry for new players in the kidney cancer therapeutics and diagnostics market?
A: The kidney cancer therapeutics and diagnostics market encompasses high entry barriers for the new players, due to the high capital and technical expertise requirement for R&D.
- What are the types of biopsies for the treatment of kidney cancer?
A: Needle core biopsy and fine-needle aspiration are the two types of kidney biopsies.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- MARKET DEFINITION
- KEY DRIVERS
- GROWING PREVALENCE OF KIDNEY CANCER CASES
- INCREASING USAGES OF MINIMALLY INVASIVE PROCESSES
- SURGING RESEARCH AND DEVELOPMENT EXPENDITURE
- KEY RESTRAINTS
- HIGH COSTS ASSOCIATED WITH THE TREATMENT AND DIAGNOSIS OF KIDNEY CANCER
- LOW RATE OF SUCCESS IN THE CLINICAL TRIALS OF KIDNEY CANCER DRUGS
- STRINGENT REGULATIONS
- KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
- THREAT OF NEW ENTRY
- THREAT OF SUBSTITUTION
- BUYER’S POWER
- SUPPLIER’S POWER
- COMPETITIVE RIVALRY
- IMPACT OF COVID-19 ON KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY INVESTMENT INSIGHT
- PORTER’S FIVE FORCE ANALYSIS
- MARKET BY CANCER TYPE
- CLEAR CELL RCC
- PAPILLARY RCC
- CHROMOPHOBE RCC
- UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
- OTHER KIDNEY CANCERS
- MARKET BY COMPONENT
- DRUGS
- DRUGS BY THERAPEUTIC CLASS
- TARGETED THERAPY
- IMMUNOTHERAPY
- OTHER THERAPEUTIC CLASS
- DRUGS BY PHARMACOLOGIC CLASS
- ANGIOGENESIS INHIBITORS
- MTOR INHIBITORS
- MONOCLONAL ANTIBODIES
- CYTOKINE IMMUNOTHERAPY (IL-2)
- DRUGS BY THERAPEUTIC CLASS
- DIAGNOSTICS
- IMAGING TEST
- BIOPSY
- BLOOD TEST
- OTHER DIAGNOSTICS
- DRUGS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- THE UNITED STATES
- CANADA
- EUROPE
- GERMANY
- THE UNITED KINGDOM
- FRANCE
- ITALY
- RUSSIA
- BELGIUM
- POLAND
- REST OF EUROPE
- ASIA PACIFIC
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- AUSTRALIA & NEW ZEALAND
- THAILAND
- INDONESIA
- VIETNAM
- REST OF ASIA PACIFIC
- REST OF WORLD
- LATIN AMERICA
- MIDDLE EAST & AFRICA
- NORTH AMERICA
- COMPANY PROFILES
- ABBOTT LABORATORIES
- AMGEN INC
- BAYER AG
- BECTON, DICKINSON AND COMPANY (BD)
- BRISTOL-MYERS SQUIBB COMPANY
- EXELIXIS
- HOFFMANN-LA ROCHE
- MERCK & CO INC
- MERCK KGAA
- NOVARTIS INTERNATIONAL AG
- NXSTAGE MEDICAL INC
- PFIZER INC
- SEATTLE GENETIC
TABLE LIST
TABLE 1: MARKET SNAPSHOT – KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
TABLE 2: RISK FACTORS DEVELOPING KIDNEY CANCER
TABLE 3: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 5: GLOBAL CLEAR CELL RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: GLOBAL CLEAR CELL RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 7: GLOBAL PAPILLARY RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 8: GLOBAL PAPILLARY RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 9: GLOBAL CHROMOPHOBE RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 10: GLOBAL CHROMOPHOBE RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 11: GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 12: GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 13: GLOBAL OTHER KIDNEY CANCERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 14: GLOBAL OTHER KIDNEY CANCERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 15: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 16: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 17: GLOBAL DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 18: GLOBAL DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 19: GLOBAL THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 20: GLOBAL THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 21: GLOBAL TARGETED THERAPY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 22: GLOBAL TARGETED THERAPY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 23: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 24: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 25: GLOBAL OTHER THERAPEUTIC CLASS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 26: GLOBAL OTHER THERAPEUTIC CLASS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 27: GLOBAL PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 28: GLOBAL PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 29: GLOBAL ANGIOGENESIS INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 30: GLOBAL ANGIOGENESIS INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 31: GLOBAL MTOR INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 32: GLOBAL MTOR INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 33: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 34: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 35: GLOBAL CYTOKINE IMMUNOTHERAPY (IL-2) MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 36: GLOBAL CYTOKINE IMMUNOTHERAPY (IL-2) MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 37: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 38: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 39: GLOBAL DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 40: GLOBAL DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 41: GLOBAL IMAGING TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 42: GLOBAL IMAGING TEST MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 43: GLOBAL BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 44: GLOBAL BIOPSY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 45: GLOBAL BLOOD TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 46: GLOBAL BLOOD TEST MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 47: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 48: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 49: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 50: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 51: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 52: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 53: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 54: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 55: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 56: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 57: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 58: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
FIGURE LIST
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, IN 2019
FIGURE 5: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CLEAR CELL RCC, 2019-2028 (IN $ MILLION)
FIGURE 6: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY PAPILLARY RCC, 2019-2028 (IN $ MILLION)
FIGURE 7: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CHROMOPHOBE RCC, 2019-2028 (IN $ MILLION)
FIGURE 8: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA, 2019-2028 (IN $ MILLION)
FIGURE 9: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY OTHER KIDNEY CANCERS, 2019-2028 (IN $ MILLION)
FIGURE 10: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, IN 2019
FIGURE 11: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUGS, 2019-2028 (IN $ MILLION)
FIGURE 12: GLOBAL THERAPEUTIC DRUG CLASS MARKET, BY TARGETED THERAPY, 2019-2028 (IN $ MILLION)
FIGURE 13: GLOBAL THERAPEUTIC DRUG CLASS MARKET, BY IMMUNOTHERAPY, 2019-2028 (IN $ MILLION)
FIGURE 14: GLOBAL THERAPEUTIC DRUG CLASS MARKET, BY OTHER THERAPEUTIC CLASS, 2019-2028 (IN $ MILLION)
FIGURE 15: GLOBAL PHARMACOLOGIC CLASS MARKET, BY ANGIOGENESIS INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 16: GLOBAL PHARMACOLOGIC CLASS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 17: GLOBAL PHARMACOLOGIC CLASS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
FIGURE 18: GLOBAL PHARMACOLOGIC CLASS MARKET, BY CYTOKINE IMMUNOTHERAPY (IL-2), 2019-2028 (IN $ MILLION)
FIGURE 19: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2019-2028 (IN $ MILLION)
FIGURE 20: GLOBAL DIAGNOSTICS MARKET, BY IMAGING TEST, 2019-2028 (IN $ MILLION)
FIGURE 21: GLOBAL DIAGNOSTICS MARKET, BY BIOPSY, 2019-2028 (IN $ MILLION)
FIGURE 22: GLOBAL DIAGNOSTICS MARKET, BY BLOOD TEST, 2019-2028 (IN $ MILLION)
FIGURE 23: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2019-2028 (IN $ MILLION)
FIGURE 24: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
FIGURE 25: THE UNITED STATES KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 26: CANADA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 27: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
FIGURE 28: GERMANY KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 29: THE UNITED KINGDOM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 30: FRANCE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 31: ITALY KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 32: RUSSIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 33: BELGIUM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 34: POLAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 35: REST OF EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 36: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
FIGURE 37: CHINA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 38: JAPAN KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 39: INDIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 40: SOUTH KOREA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 41: AUSTRALIA & NEW ZEALAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 42: THAILAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 43: INDONESIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 44: VIETNAM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 45: REST OF ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 46: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 47: LATIN AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 48: MIDDLE EAST & AFRICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
- MARKET BY CANCER TYPE
- CLEAR CELL RCC
- PAPILLARY RCC
- CHROMOPHOBE RCC
- UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
- OTHER KIDNEY CANCERS
- MARKET BY COMPONENT
- DRUGS
- DRUGS BY THERAPEUTIC CLASS
- TARGETED THERAPY
- IMMUNOTHERAPY
- OTHER THERAPEUTIC CLASS
- DRUGS BY PHARMACOLOGIC CLASS
- ANGIOGENESIS INHIBITORS
- MTOR INHIBITORS
- MONOCLONAL ANTIBODIES
- CYTOKINE IMMUNOTHERAPY (IL-2)
- DRUGS BY THERAPEUTIC CLASS
- DIAGNOSTICS
- IMAGING TEST
- BIOPSY
- BLOOD TEST
- OTHER DIAGNOSTICS
- DRUGS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- THE UNITED STATES
- CANADA
- EUROPE
- GERMANY
- THE UNITED KINGDOM
- FRANCE
- ITALY
- RUSSIA
- BELGIUM
- POLAND
- REST OF EUROPE
- ASIA PACIFIC
- CHINA
- JAPAN
- INDIA
- SOUTH KOREA
- AUSTRALIA & NEW ZEALAND
- THAILAND
- INDONESIA
- VIETNAM
- REST OF ASIA PACIFIC
- REST OF WORLD
- LATIN AMERICA
- MIDDLE EAST & AFRICA
- NORTH AMERICA
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.